39 related articles for article (PubMed ID: 12056330)
21. [Evaluation of cancer risk by ionizing radiation after dosimetry revision of Hiroshima and Nagasaki].
Breckow J
Med Klin (Munich); 1991 Feb; 86(2):92-8. PubMed ID: 2030666
[No Abstract] [Full Text] [Related]
22. Risk of cancer among atomic bomb survivors.
Shimizu Y; Kato H; Schull WJ
J Radiat Res; 1991 Dec; 32 Suppl 2():54-63. PubMed ID: 1823367
[TBL] [Abstract][Full Text] [Related]
23. Workshop Report on Atomic Bomb Dosimetry--Review of Dose Related Factors for the Evaluation of Exposures to Residual Radiation at Hiroshima and Nagasaki.
Kerr GD; Egbert SD; Al-Nabulsi I; Bailiff IK; Beck HL; Belukha IG; Cockayne JE; Cullings HM; Eckerman KF; Granovskaya E; Grant EJ; Hoshi M; Kaul DC; Kryuchkov V; Mannis D; Ohtaki M; Otani K; Shinkarev S; Simon SL; Spriggs GD; Stepanenko VF; Stricklin D; Weiss JF; Weitz RL; Woda C; Worthington PR; Yamamoto K; Young RW
Health Phys; 2015 Dec; 109(6):582-600. PubMed ID: 26509626
[TBL] [Abstract][Full Text] [Related]
24. Cancer risks and biomarker studies in the atomic bomb survivors.
Preston D
Stem Cells; 1995 May; 13 Suppl 1():40-8. PubMed ID: 7488967
[TBL] [Abstract][Full Text] [Related]
25. Dosimetric aspects of exposure of the population to ionizing radiation.
Broerse JJ; Dennis JA
Int J Radiat Biol; 1990 Apr; 57(4):633-45. PubMed ID: 1969897
[TBL] [Abstract][Full Text] [Related]
26. Risk estimates for radiation-induced cancer--the epidemiological evidence.
Kellerer AM
Radiat Environ Biophys; 2000 Mar; 39(1):17-24. PubMed ID: 10789891
[TBL] [Abstract][Full Text] [Related]
27. The use of biologically based cancer risk models in radiation epidemiology.
Krewski D; Zielinski JM; Hazelton WD; Garner MJ; Moolgavkar SH
Radiat Prot Dosimetry; 2003; 104(4):367-76. PubMed ID: 14579893
[TBL] [Abstract][Full Text] [Related]
28. Biological parameters for lung cancer in mathematical models of carcinogenesis.
Jacob P; Jacob V
Radiat Prot Dosimetry; 2003; 104(4):357-66. PubMed ID: 14579892
[TBL] [Abstract][Full Text] [Related]
29. Reassessment of the cancer mortality risk among Hiroshima atomic-bomb survivors using a new dosimetry system, ABS2000D, compared with ABS93D.
Katayama H; Matsuura M; Endo S; Hoshi M; Ohtaki M; Hayakawa N
J Radiat Res; 2002 Mar; 43(1):53-64. PubMed ID: 12056330
[TBL] [Abstract][Full Text] [Related]
30. Cancer and non-cancer effects in Japanese atomic bomb survivors.
Little MP
J Radiol Prot; 2009 Jun; 29(2A):A43-59. PubMed ID: 19454804
[TBL] [Abstract][Full Text] [Related]
31. Mortality among atomic bomb survivors.
Shimizu Y; Kato H; Schull WJ
J Radiat Res; 1991 Mar; 32 Suppl():212-30. PubMed ID: 1762109
[TBL] [Abstract][Full Text] [Related]
32. Studies on the Hiroshima and Nagasaki survivors, and their use in estimating radiation risks.
Muirhead CR
Radiat Prot Dosimetry; 2003; 104(4):331-5. PubMed ID: 14579889
[TBL] [Abstract][Full Text] [Related]
33. Neutron relative biological effectiveness in Hiroshima and Nagasaki atomic bomb survivors: a critical review.
Sasaki MS; Endo S; Hoshi M; Nomura T
J Radiat Res; 2016 Nov; 57(6):583-595. PubMed ID: 27614201
[TBL] [Abstract][Full Text] [Related]
34. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987.
Thompson DE; Mabuchi K; Ron E; Soda M; Tokunaga M; Ochikubo S; Sugimoto S; Ikeda T; Terasaki M; Izumi S
Radiat Res; 1994 Feb; 137(2 Suppl):S17-67. PubMed ID: 8127952
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
